Dapagliflozin

Dapagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Kasichayanula 2014, Plosker 2014).
Administered orally once a day.

Low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (EMA 2017, Plosker 2014).

Since the last update, we have not found published data on its excretion in breast milk.

Its high percentage of protein binding (EMA 2017) makes its transfer to milk in significant quantities unlikely, but the low molecular weight and its elimination half-life greater than 12 hours could facilitate a possible transfer.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Diet, exercise and breastfeeding improve blood glucose levels.

• Maternal Diabetes Mellitus (Low Risk probable)

Alternatives

• Sport (Very Low Risk)
• Hypo-Caloric Diet (Very Low Risk)
• Acarbose (Very Low Risk)
• Chlorpropamide (Low Risk probable)
• Saxagliptin (Low Risk probable)
• Tolbutamide (Very Low Risk)
• Miglitol (Very Low Risk)
• Glibenclamide (Very Low Risk)
• Metformin Hydrochloride (Very Low Risk)